home.aspx

 
.

OPTIMIZING ONCOLOGY TRIALS WITH A CTDNA TEST CUSTOM-BUILT FOR MRD AND MOLECULAR MONITORING

SHARESHARESHARE
Join this webinar to discover the advantages of using Signatura™ (RUO), a novel assay custom-designed for each patient that detects circulating tumour DNA (ctDNA) with high sensitivity and specificity to monitor molecular residual disease, early recurrence, and treatment response across solid tumours. Learn about the latest clinical data for Signatura and explore how this unique ctDNA assay can be applied in pharmaceutical development and oncology clinical study design, potentially increasing the probability of trial success, reduce the time to trial readout, and decrease clinical trial costs